NetraMark will be attending the Clinical Trials on Alzheimer’s Disease (CTAD) conference on 16-19 November 2026 in Boston, MA, USA.
The Clinical Trials on Alzheimer’s Disease (CTAD) conference is an annual international scientific meeting dedicated exclusively to Alzheimer’s disease (AD) clinical research, new therapeutics, and trial design.
Send us a message or set up a time to chat with our attending team below!
Attending Team
Josh Spiegel
President, NetraMark
Dr. Jan Sedway, PhD
Senior VP, Clinical Science, NetraMark
What Is NetraAI?
NetraAI is an AI-driven clinical intelligence platform, purpose-built to analyze all collected participant data across small, complex clinical trial datasets.
Designed to address the challenges of heterogeneity, NetraAI reveals patient-level response structure that informs sponsors and biotechs of the minimal baseline characteristic combinations found to be driving treatment response and placebo response signals across trial populations.
Access to this data that is often obscured by traditional population averaging enables sponsors to inform clinical development decisions before future trial designs are locked.